Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Actuate Therapeutics IncNASDAQ: ACTU
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Short-term investments amounts to 0.0% of total assets for ACTU, versus a peer median of 35.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $321.65M USD | +3120.4% | -30.2% | 63.5% | |
| Mar 2026 | $203.07M USD | -4.6% | -9.1% | 54.6% | |
| Mar 2026 | $129.55M USD | -59.1% | -30.2% | 54.0% | |
| Mar 2026 | $90.15M USD | +66.5% | — | 57.7% | |
| Mar 2026 | CHF 14.52M CHF | -70.7% | -59.9% | 16.6% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ACTU) | — | -4.6% | -30.2% | 35.3% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.